Haegarda® (C1 Esterase Inhibitor Subcutaneous [Human]) (Subcutaneous)

Document Number: IC-0307

Last Review Date: 10/01/2026
Date of Origin: 08/1/2017
Dates Reviewed: 08/2017, 12/2017, 03/2018, 06/2018, 10/2018, 10/2019, 03/2020, 10/2020, 10/2021, 10/2022, 10/2023, 08/2024, 08/2025, 10/2026

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 12 months (365 days).
- Renewal: Prior authorization validity may be renewed every 12 months (365 days) thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:
- 5,600 billable units per 28 days

III. Initial Approval Criteria [1,15-17,21-23]

Prior authorization validity is provided in the following conditions:

- Member is at least 6 years of age; **AND**

Universal Criteria

- Must be prescribed by, or in consultation with, a specialist in allergy, immunology, hematology, pulmonology, or medical genetics; **AND**
- Will not be used in combination with another therapy indicated for the prophylaxis of hereditary angioedema (HAE) attacks; ***NOTE:*** *Requests for combination therapy with Cinryze is allowable when Cinryze is requested as short-term prophylaxis ONLY*; **AND**
- Provider will confirm member has been counseled to avoid possible medication triggers for HAE attacks (e.g. estrogen-containing medications, ACE inhibitors, etc.); **AND**

Prophylaxis to Prevent Hereditary Angioedema (HAE) Attacks † ‡ Φ

- Member has a history of ANY of the following:
  - Recurrent swelling of mucous membranes, skin surface, or subcutaneous tissue
  - Recurrent abdominal attacks with any of the following: severe abdominal pain, nausea, vomiting, or diarrhea
  - Episodes of upper airway (e.g., mouth, tongue, larynx, etc.) edema
  - Prodromal signs and symptoms (e.g., anxiety, nausea, paresthesia, fatigue, etc.) preceding angioedema attacks

© 2026 Prime Therapeutics Management, LLC
Proprietary & Confidential.

- Positive family history of HAE; **AND**

- Other causes of angioedema have been ruled out (e.g., drug-induced angioedema, mast cell induced angioedema, acquired angioedema due to C1-INH deficiency, etc.); **AND**
- Member has demonstrated that long-term prophylactic HAE treatment is necessary based on the provider's assessment of the member's disease activity, quality of life, availability of health care resources, and/or failure to achieve adequate control by appropriate acute HAE attack therapy; **AND**
- Diagnosis of HAE has been confirmed as one of the following:
  - Member has HAE due to C1 inhibitor deficiency (HAE-C1-INH) Type 1 or 2; **AND**
    - Member has a current or historical C1-INH antigenic level below the lower limit of normal as defined by the laboratory performing the test; **OR**
    - Member has a current or historical C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test; **OR**
    - Genetic testing confirming pathogenic mutation(s) in *SERPING1;* **OR**
  - Member has HAE with normal C1INH (HAE-nC1-INH); **AND**
    - Member has a current or historical normal C1-INH level (e.g., C1-INH antigenic level, C1-INH functional level) as defined by the laboratory performing the test; **AND**
      - Member has a confirmed presence of known HAE-causing mutation(s) in the gene(s) for factor XII (*F12),* angiopoietin-1 *(ANGPT1),* plasminogen *(PLG),* kininogen-1 *(KNG1),* myoferlin *(MYOF)*, and/or heparan sulfate-glucosamine 3-O-sulfotransferase 6 (*HS3ST6)*; **OR**
      - Member has recurrent angioedema attacks without hives that are refractory to a 4-week trial of high-dose antihistamines (i.e. second-generation H1 antagonist at four times the standard dose); **AND**
    - Member must have demonstrated ONE of the following:
      - Prior beneficial response to a therapy indicated for the treatment of acute HAE attacks; **OR**
      - Inadequate response or intolerance to an adequate trial of another prophylactic HAE therapy such as an antifibrinolytic agent (e.g., tranexamic acid [TXA] or aminocaproic acid), a 17α-alkylated androgen (e.g., danazol), and/or progestin therapy (specific to females)

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

IV. Renewal Criteria[1,21-23]

Prior authorization validity can be renewed based upon the following criteria:

- Member continues to meet the universal and other indication-specific relevant criteria identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, thromboembolic events, etc.; **AND**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2026 Prime Therapeutics Management, LLC

- The member has experienced clinical benefit from therapy (e.g., reduced attack severity and/or frequency, shortened attack duration, etc.)

V. Dosage/Administration[1]

Indication	Dose
Prophylaxis to Prevent Hereditary Angioedema (HAE) attacks	60 IU/kg body weight injected subcutaneously twice weekly (every 3 or 4 days) ***Note:** Members may self-administer Haegarda after being instructed by their healthcare provider.*

VI. Billing Code/Availability Information

HCPCS Code:

- J0599 – Injection, c-1 esterase inhibitor (human), (haegarda), 10 units; 1 billable unit = 10 IU

NDC(s):

- Haegarda 2000 IU single-dose vial kit: 63833-0828-xx
- Haegarda 3000 IU single-dose vial kit: 63833-0829-xx

VII. References

1. Haegarda [package insert]. Kankakee, IL; CSL Behring LLC; January 2022. Accessed July 2026.
2. Longhurst H, Cicardi M, Craig T, et al.; COMPACT Investigators. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Eng J Med. 2017;376:1131-1140.
3. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. 2004 Sep;114(3):629-37.
4. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. Mar-Apr 2009;19(2):147-151.
5. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.
6. Craig T, Aygören-Pürsün E, Bork K, et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J. 2012 Dec;5(12):182-99.
7. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379.
8. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Asthma Clin Immunol. 2014 Oct 24;10(1):50. doi: 10.1186/1710-1492-10-50.
9. Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013 Jun;131(6):1491-3. doi: 10.1016/j.jaci.2013.03.034.
10. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013 Sep-Oct;1(5):458-67.

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2026 Prime Therapeutics Management, LLC

11. Frank MM, Zuraw B, Banerji A, et al. Management of children with Hereditary Angioedema due to C1 Inhibitor deficiency. Pediatrics. 2016 Nov. 135(5)
12. Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy Asthma Proc. 2012;33 Suppl 1:145-156.
13. Maurer M, Mager M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018 Jan 10. doi: 10.1111/all.13384.
14. Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. Ann Alergy Asthma Immunol. 2012;109:395-402.
15. Wintenberger C, Boccon-Gibod I, Launay D, et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol. 2014 Oct; 178(1): 112–117.
16. Saule C, Boccon-Gibod I, Fain O, et al. Benefits of progestin contraception in non-allergic angioedema. Clin Exp Allergy. 2013 Apr;43(4):475-82.
17. Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema; a double-blind study. N Engl J Med. 1972:286:808-812.
18. Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema Guideline. Allergy Asthma Clin Immunol. 2019; 15: 72. Published online 2019 Nov 25. doi: 10.1186/s13223-019-0376-8.
19. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3. doi: 10.1016/j.jaip.2020.08.046.
20. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. Allergy. 2021 Nov 22. doi: 10.1111/all.15214.
21. Zuraw, B.L., Bork, K., Bouillet, L. et al. Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment. Clinic Rev Allerg Immunol 68, 24 (2025).
22. Vázquez DO, Giavina-Bianchi P, Josviack D, et al. The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities, World Allergy Organ J. 2026 Mar 19;19(5):101335. doi: 10.1016/j.waojou.2026.101335. PMID: 42165046; PMCID: PMC13184495.
23. Betschel, S., Binkley, K., Borici-Mazi, R. et al. The International/Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol 22, 24 (2026). https://doi.org/10.1186/s13223-025-00999-8

Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD)

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2026 Prime Therapeutics Management, LLC

Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime's assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	No: PA not a priority
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D84.1	Defects in the complement system

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: https://www.cms.gov/medicare-coverage-database/search.aspx. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	**Applicable State/US Territory**	**Contractor**
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	Wellpoint Federal
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2026 Prime Therapeutics Management, LLC

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	**Applicable State/US Territory**	**Contractor**
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	Wellpoint Federal
15	KY, OH	CGS Administrators, LLC

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2026 Prime Therapeutics Management, LLC